Dapagliflozin Granted Priority Review for Adults With Heart Failure Dapagliflozin Granted Priority Review for Adults With Heart Failure

The application for the SGLT2 inhibitor is based on the results from the landmark phase 3 DAPA-HF trial.Medscape Medical News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Related Links:

Type 2 diabetes mellitus (T2DM) represents a major health problem,1 contributing to 11.3% of deaths globally.2 Cardiovascular disease (CVD) still affects a large proportion of patients,3 despite the fact that incidence rates of cardiovascular outcomes have decreased over the last two decades.4 Heart failure (HF) is a main contributor of cardiovascular morbidity and mortality among patients with T2DM,5 who feature an almost twofold increase in the risk of HF, with women having a greater risk compared to men.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
Publication date: Available online 9 October 2020Source: American Heart JournalAuthor(s): Henrik Wiggers, Lars Køber, Gunnar Gislason, Morten Schou, Mikael Kjær Poulsen, Søren Vraa, Olav Wendelbo Nielsen, Niels Eske Bruun, Helene Nørrelund, Malene Hollingdal, Anders Barasa, Morten Bøttcher, Karen Dodt, Vibeke Brogaard Hansen, Gitte Nielsen, Anne Sejr Knudsen, Jens Lomholdt, Kirsten Vilain Mikkelsen, Bartlomiej Jonczy, Jens Brønnum-Schou
Source: American Heart Journal - Category: Cardiology Source Type: research
Authors: Nguyen C, Luthra R, Kuti E, Willey VJ Abstract Background: Description of risk of cardiovascular (CV) events associated with diabetes is evolving. This US-based real-world study estimated risk of future CV events and heart failure (HF) from type 2 diabetes (T2DM)-only, prior CV events-only, or T2DM + prior CV events, versus controls, and evaluated healthcare resource utilization (HCRU) and costs.Methods and Materials: This retrospective cohort study queried claims and mortality data for 638,301 patients: T2DM-only (377,205); prior CV events-only (130,964); both T2DM + prior CV e...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
AbstractPurpose of ReviewThis narrative review makes the case for greater efforts to reduce cardiovascular disease (CVD) risk in women with diabetes.Recent FindingsIn a recent meta-analysis including five CVOTs of diabetes medications with 46,606 subjects, women (vs men) with type 2 diabetes had a higher relative risk for stroke (RR 1.28; 95% CI 1.09, 1.50) and heart failure (1.30; 1.21, 1.40). Prior studies found higher “within-gender” RR for CVD mortality in women with diabetes although men have an absolute higher risk. Women with prior gestational diabetes mellitus (GDM) have a 2-fold higher CVD risk than th...
Source: Current Diabetes Reports - Category: Endocrinology Source Type: research
(Penn State) A large, international study of COVID-19 patients confirmed that cardiovascular disease, hypertension, diabetes, congestive heart failure, chronic kidney disease, stroke and cancer can increase a patient's risk of dying from the virus.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
by Mehrshad Sadria, Anita T. Layton Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) are frequently prescribed for a range of diseases including hypertension, proteinuric chronic kidney disease, and heart failure. There is evidence indicating that these drugs upregulate ACE2, a key component of the renin-angiotensin system (RAS) and is found on the cells of a number of tissues, including the epithelial cells in the lungs. While ACE2 has a beneficial role in many diseases such as hypertension, diabetes, and cardiovascular disease, it also serves as a receptor for both SARS-CoV and ...
Source: PLoS Computational Biology - Category: Biology Authors: Source Type: research
AbstractVitamin C (Vit C) is an ideal antioxidant as it is easily available, water soluble, very potent, least toxic, regenerates other antioxidants particularly Vit E, and acts as a cofactor for different enzymes. It has received much attention due to its ability in limiting reactive oxygen species, oxidative stress, and nitrosative stress, as well as it helps to maintain some of the normal metabolic functions of the cell. However, over 140 clinical trials using Vit C in different pathological conditions such as myocardial infarction, gastritis, diabetes, hypertension, stroke, and cancer have yielded inconsistent results....
Source: Heart Failure Reviews - Category: Cardiology Source Type: research
AbstractAimsRheumatoid arthritis (RA) is a systemic inflammatory autoimmune disorder that not only affects peripheral joints but also increases the risk for cardiovascular disease (CVD) and mortality. Heart failure (HF) appears to be one of the most important contributors to the excess mortality risk among patients with RA. We assessed the incidence of HF in patients with RA compared with age ‐matched and sex‐matched non‐RA subjects, after accounting for traditional cardiovascular risk factors and clinical ischemic heart disease.Methods and resultsWe performed an aggregate analysis on three studies of RA patients hav...
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research
Abstract Background: In patients with type 2 diabetes mellitus (T2DM), sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure (HHF). We assessed the effect of ertugliflozin on HHF and related outcomes. Methods: VERTIS CV, a double-blind, placebo-controlled trial, randomized patients with T2DM and atherosclerotic cardiovascular (CV) disease to once-daily ertugliflozin 5 mg, 15 mg or placebo. Prespecified secondary analyses compared ertugliflozin (pooled doses) versus placebo on time to first event of HHF and composite of HHF/CV death, overall and stratified by prespec...
Source: Circulation - Category: Cardiology Authors: Tags: Circulation Source Type: research
Conclusion IRRHs in patients discharged for acute decompensated heart fail independently predicted worse long-term survival. We further identified independent predictors of IRRHs. These findings warrant future studies for tackling IRRH.
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Research articles: Heart failure Source Type: research
More News: Cardiology | Dapagliflozin | Diabetes | Endocrinology | Forxiga | Heart | Heart Failure | SGLT2 Inhibitors